Skip to content

Biomarkers Based EArly Diagnosis of STroke Subtype Cohort(Bio-EAST)

Biomarkers Based EArly Diagnosis of STroke Subtype Cohort, Bio-EAST

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07003477
Acronym
Bio-EAST
Enrollment
527
Registered
2025-06-04
Start date
2025-06-12
Completion date
2028-11-30
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, Intracerebral hemorrhage, GFAP (glial fibrillary acidic protein), Pre-hospital diagnosis

Brief summary

Intracerebral hemorrhage carries high rates of mortality and disability, imposes a significant societal burden. Based on findings from our previous multicenter randomized controlled clinical trial (INTERACT4), we revealed that initiating intensive blood pressure reduction therapy within 2 hours of onset in ambulances can markedly enhance the prognosis of patients with intracerebral hemorrhage. Nevertheless, the lack of rapid pre-hospital diagnostic technology hinders its clinical application and promotion. Given that glial fibrillary acidic protein (GFAP), as a biomarker, has been clinically validated for its high specificity in diagnosing intracerebral hemorrhage, this project aims to leverage an industry-academia-research collaborative development model in partnership with Shanghai Jinguan Technology Co., Ltd. By focusing on the urgent need for rapid diagnosis in stroke emergency care, this project will integrate clinical resources from hospitals with technological advantages in product development from the industry. Through resource sharing and complementary strengths, we aim to develop GFAP rapid detection technology with single-molecule sensitivity utilizing internationally advanced silicon photonics technology. Our objectives further include establishing a Chinese cohort to validate the reliability of GFAP in diagnosing intracerebral hemorrhage and conducting multicenter randomized controlled clinical trials to ascertain the efficacy and safety of GFAP-guided pre-hospital intensive blood pressure reduction for patients with intracerebral hemorrhage. This study also aimed to explore other biomarkers to be combined with GFAP in order to improve its sensitivity in detecting ICH.

Interventions

DIAGNOSTIC_TESTDetection of peripheral blood biomarkers

Peripheral blood samples were collected from patients suffering from acute stroke. The concentration of the biomarker glial fibrillary acidic protein (GFAP) was then detected. This was aimed at differentiating between hemorrhagic stroke and non - hemorrhagic stroke. Time - concentration curves were constructed, thereby offering a novel potential approach for the rapid identification of stroke types within ambulances.

Sponsors

Shanghai East Hospital
Lead SponsorOTHER
Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University
CollaboratorUNKNOWN
Shanghai 7th People's Hospital
CollaboratorOTHER
Huashan Hospital
CollaboratorOTHER
Shanghai Zhongshan Hospital
CollaboratorOTHER
Fudan University
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years old; 2. Suspected stroke at emergency department arrival (FAST score ≥ 2 points, must include limb weakness); 3. Time of stroke symptom onset/last known normal within 3 hours.

Exclusion criteria

1. Coma - no response to tactile or verbal stimuli; 2. Severe comorbidities (such as tumors, severe COPD, severe heart failure, requiring assistance with daily living \[unable to walk independently\]); 3. History of epilepsy or onset with seizure; 4. Recent history of head trauma (\< 7 days); 5. Blood glucose \< 2.8 mmol/L.

Design outcomes

Primary

MeasureTime frameDescription
stroke subtypeUpon arrival at the hospital for the first timeCerebral hemorrhage diagnosed by head CT

Countries

China

Contacts

CONTACTGang Li
ligang@tongji.edu.cn+86 136 2169 1786

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026